Interestingly, Carvajal et al.22 found that both the Leu576Pro and Lys642Glu mutations responded to imatinib in the metastatic melanoma setting, supporting the possibility of expanding imatinib to adjuvant application in a high-risk stage II setting in KIT-mutated melanoma. Here, KIT is linked to melanoma.